TODD STRATEGY GROUP
TODD STRATEGY GROUP filed a Q3 report for AMERICAN MEDICAL ASSOCIATION on October 20, 2026, reporting $60,000 in lobbying income.
Lobbying for AMERICAN MEDICAL ASSOCIATION · Professional association of physicians and medical students.
-
PAUL EDATTELPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
DANIEL M TODDPreviously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
NICHOLAS UEHLECKEPreviously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
ERIC BERGRENPreviously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
KATHERINE FLEMING COTTONPreviously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
NIH Strategic Plan. HIPAA Proposed Rule. Maternal health. Health care consolidation. ICD-11 implementation and other coding issues. Public Law 119-21: One Big Beautiful Bill Act. U.S. Preventive Services Task Force (USPSTF). AMA Physician Practice benchmark survey results. Vaccines and ACIP. Telehealth policy initiatives. H.R.7148: Consolidated Appropriations Act. Long-Term Care Rate Changes.
Alternative payment model bonuses and incentive payments and freezing the qualifying provider revenue thresholds. Interoperability and Prior Authorization Final Rule. Hospital Inpatient Prospective Payment Systems. CMMI Reforms. Medicare Access and CHIP Reauthorization Act (MACRA). Accountable Care Organizations (ACOs) and Alternative Payment Models (APMs) in Medicare. Indirect practice expense. Medicare physician payment issues. MIPS quality and cost measures.
Drug shortages.